MedTrace Logo

Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?

NCT01960296 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2017-05-30

Study results available
· View outcomes & findings →

Summary

Patients who on taking clopidogrel are randomized to either continue clopidogrel into general surgery or discontinue clopidogrel 7 days before surgery. All patients resume clopidogrel after surgery. The investigators track the development of bleeding complications that may develop within 90 days of the surgery. Patients are medically cleared to be in either arm of the study by their cardiologist and surgeon. There is currently no evidence to support for or against the use continuation or discontinuation of clopidogrel prior to general surgery.

Conditions

  • Clopidogrel

Interventions

DRUG

Clopidogrel

Continue home dose of clopidogrel into surgery

DRUG

Discontinue Clopidogrel

Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.

Sponsors & Collaborators

Principal Investigators

  • Celia M Divino, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01960296 on ClinicalTrials.gov